These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24791735)

  • 1. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.
    Newall AT; Jit M; Hutubessy R
    Pharmacoeconomics; 2014 Jun; 32(6):525-31. PubMed ID: 24791735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global economic evaluations of rotavirus vaccines: A systematic review.
    Kotirum S; Vutipongsatorn N; Kongpakwattana K; Hutubessy R; Chaiyakunapruk N
    Vaccine; 2017 Jun; 35(26):3364-3386. PubMed ID: 28504193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018.
    Jit M
    Value Health; 2021 Jan; 24(1):61-66. PubMed ID: 33431154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.
    Plosker GL
    Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
    Kim SY; Sweet S; Chang J; Goldie SJ
    BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines.
    Thiboonboon K; Santatiwongchai B; Chantarastapornchit V; Rattanavipapong W; Teerawattananon Y
    Appl Health Econ Health Policy; 2016 Dec; 14(6):659-672. PubMed ID: 27475634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.
    Leech AA; Kim DD; Cohen JT; Neumann PJ
    Value Health; 2018 Jul; 21(7):759-761. PubMed ID: 30005746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thresholds for the cost-effectiveness of interventions: alternative approaches.
    Marseille E; Larson B; Kazi DS; Kahn JG; Rosen S
    Bull World Health Organ; 2015 Feb; 93(2):118-24. PubMed ID: 25883405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human papillomavirus vaccination: a review of the cost-effectiveness studies.
    Giraldi G; Martinoli L; De Luca d'Alessandro E
    Clin Ter; 2014; 165(6):e426-32. PubMed ID: 25524200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
    Fesenfeld M; Hutubessy R; Jit M
    Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.
    Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS
    Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.
    Glassman A; Cañón O; Silverman R
    Value Health; 2016 Dec; 19(8):913-920. PubMed ID: 27987640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".
    Gandjour A
    Pharmacoeconomics; 2014 Dec; 32(12):1245-6. PubMed ID: 25253682
    [No Abstract]   [Full Text] [Related]  

  • 18. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.
    Pichon-Riviere A; Drummond M; Palacios A; Garcia-Marti S; Augustovski F
    Lancet Glob Health; 2023 Jun; 11(6):e833-e842. PubMed ID: 37202020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
    Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
    Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.